Brief: Wilex unit Heidelberg Pharma signs option agreement with Max Delbrück Center

Heidelberg Pharma AG

19/09/2016 06:18

Sept 19 (Reuters) - Wilex AG  WL6G.DE : 
    * Subsidiary Heidelberg Pharma signs option agreement with 
Max Delbrück Center 
    * Heidelberg Pharma starts internal development project for 
multiple myeloma based on its proprietary atac (antibody 
targeted amanitin conjugates) technology with BCMA antibodies 
    * Financial details are not disclosed but will not have a 
material impact on Wilex' cash guidance 
 
Source text for Eikon:  ID:nEQ9hS8ZLa  
Further company coverage:  WL6G.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 722 0920;))